Top Dividend Stocks On SEHK To Consider In August 2024

As global markets react to economic data and shifts in investor sentiment, the Hong Kong market has shown resilience amid broader uncertainties. With the Hang Seng Index experiencing modest declines, dividend stocks on the SEHK remain a compelling option for investors seeking stable returns in volatile times. In this environment, selecting dividend stocks with strong fundamentals and consistent payout histories can provide a reliable income stream and mitigate some of the risks associated with market fluctuations.

Top 10 Dividend Stocks In Hong Kong

Name	Dividend Yield	Dividend Rating
China Construction Bank (SEHK:939)	8.22%	★★★★★★
Chongqing Rural Commercial Bank (SEHK:3618)	8.20%	★★★★★★
Lenovo Group (SEHK:992)	3.95%	★★★★★☆
Luk Fook Holdings (International) (SEHK:590)	9.14%	★★★★★☆
Chow Tai Fook Jewellery Group (SEHK:1929)	8.23%	★★★★★☆
S.A.S. Dragon Holdings (SEHK:1184)	9.28%	★★★★★☆
Bank of China (SEHK:3988)	7.80%	★★★★★☆
Zhejiang Expressway (SEHK:576)	6.89%	★★★★★☆
China Mobile (SEHK:941)	6.76%	★★★★★☆
Sinopharm Group (SEHK:1099)	5.10%	★★★★★☆

Click here to see the full list of 86 stocks from our Top SEHK Dividend Stocks screener.

Here we highlight a subset of our preferred stocks from the screener.

Sinopharm Group (SEHK:1099)

Simply Wall St Dividend Rating: ★★★★★☆

Overview: Sinopharm Group Co. Ltd., with a market cap of HK$58.48 billion, operates in the wholesale and retail sectors for pharmaceuticals, medical devices, and healthcare products in the People’s Republic of China.

Operations: Sinopharm Group Co. Ltd., along with its subsidiaries, generates revenue through the wholesale and retail distribution of pharmaceuticals, medical devices, and healthcare products in China.

Dividend Yield: 5.1%

Sinopharm Group declared a final dividend of RMB 0.87 per share for FY2023, with payment set for 13 August 2024. The company's dividends have been stable and growing over the past decade, supported by a low payout ratio (30.6%) and cash payout ratio (34%), ensuring sustainability. Trading at significant value below its estimated fair value, Sinopharm offers reliable dividends despite not being among Hong Kong's top-tier payers. Recent AGM proposals may impact future capital structure and share issuance policies.

• Unlock comprehensive insights into our analysis of Sinopharm Group stock in this dividend report.
• Insights from our recent valuation report point to the potential undervaluation of Sinopharm Group shares in the market.

Man Wah Holdings (SEHK:1999)

Simply Wall St Dividend Rating: ★★★★☆☆

Overview: Man Wah Holdings Limited is an investment holding company involved in the manufacture, wholesale, trading, and distribution of sofas and ancillary products across China, Europe, Vietnam, Mexico, and internationally with a market cap of HK$17.80 billion.

Operations: Man Wah Holdings Limited generates revenue primarily from Sofa and Ancillary Products (HK$12.66 billion), Bedding and Ancillary Products (HK$2.99 billion), Home Group Business (HK$674.14 million), Other Products (HK$1.82 billion), and Other Businesses (HK$270.78 million).

Dividend Yield: 6.5%

Man Wah Holdings approved a final dividend of HK$0.15 per share for FY2024, with payment on 22 July 2024. Despite recent earnings growth and a reasonable payout ratio (50.8%), its dividends have been volatile over the past decade, making them less reliable. The company’s cash payout ratio stands at 84.4%, indicating dividends are covered by cash flows but leave limited room for flexibility. Recent bylaw amendments may offer future operational benefits regarding treasury shares.

• Click to explore a detailed breakdown of our findings in Man Wah Holdings' dividend report.
• Insights from our recent valuation report point to the potential overvaluation of Man Wah Holdings shares in the market.

China Medical System Holdings (SEHK:867)

Simply Wall St Dividend Rating: ★★★★☆☆

Overview: China Medical System Holdings Limited is an investment holding company that manufactures, sells, markets, and promotes pharmaceutical products in the People’s Republic of China with a market cap of HK$15.64 billion.

Operations: The company's primary revenue segment is the marketing, promotion, sales, and manufacturing of pharmaceutical products, generating CN¥8.01 billion.

Dividend Yield: 6.7%

China Medical System Holdings' dividend payments have been volatile over the past decade, with a recent final dividend of HK$0.086 per share for 2023. Despite a low payout ratio (40%), suggesting dividends are covered by earnings and cash flow, the stock's yield (6.67%) is below the top 25% in Hong Kong. Recent clinical developments, including phase III trials for ruxolitinib cream and approval of Lumeblue®, indicate potential growth but do not guarantee immediate dividend stability.

• Get an in-depth perspective on China Medical System Holdings' performance by reading our dividend report here.
• In light of our recent valuation report, it seems possible that China Medical System Holdings is trading behind its estimated value.

Next Steps

• Take a closer look at our Top SEHK Dividend Stocks list of 86 companies by clicking here.
• Have you diversified into these companies? Leverage the power of Simply Wall St's portfolio to keep a close eye on market movements affecting your investments.
• Simply Wall St is a revolutionary app designed for long-term stock investors, it's free and covers every market in the world.

Looking For Alternative Opportunities?

• Explore high-performing small cap companies that haven't yet garnered significant analyst attention.
• Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management.
• Find companies with promising cash flow potential yet trading below their fair value.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com